The gut is a digestive organ that absorbs nutrients but also plays a vital role in immune response and defense against external compounds.The complex interaction between the gut microbiota and other organs including t...The gut is a digestive organ that absorbs nutrients but also plays a vital role in immune response and defense against external compounds.The complex interaction between the gut microbiota and other organs including the immune system of the host has been known in various contexts,yielding the notion of‘axes’between the gut and other organs.While the presence of various gut-organ axes has been reported,the lack of adequate in vitro model systems for studying this interaction has restricted a deeper insight into these phenomena.Recently developed microphysiological systems(MPS),also known as organ-on-a-chip,allow researchers to study complex interactions between diverse organs,and here we provide a review of how recently developed gut-on-a-chip systems are used for building models of various diseases that were difficult to study.展开更多
pioids are commonly used for treating chronic pain.However,with continued use,they may induce tolerance and/or hyperalgesia,which limits therapeutic efficacy.The human mechanisms of opioid-induced tolerance and hypera...pioids are commonly used for treating chronic pain.However,with continued use,they may induce tolerance and/or hyperalgesia,which limits therapeutic efficacy.The human mechanisms of opioid-induced tolerance and hyperalgesia are significantly understudied,in part,because current models cannot fully recapitulate human pathology.Here,we engineered novel human spinal microphysiological systems(MPSs)integrated with plug-and-play neural activity sensing for modeling human nociception and opioid-induced tolerance.Each spinal MPS consists of a flattened human spinal cord organoid derived from human stem cells and a 3D printed organoid holder device for plug-and-play neural activity measurement.We found that the flattened organoid design of MPSs not only reduces hypoxia and necrosis in the organoids,but also promotes their neuron maturation,neural activity,and functional development.We further demonstrated that prolonged opioid exposure resulted in neurochemical correlates of opioid tolerance and hyperalgesia,as measured by altered neural activity,and downregulation ofμ-opioid receptor expression of human spinal MPSs.The MPSs are scalable,cost-effective,easy-to-use,and compatible with commonly-used well-plates,thus allowing plug-and-play measurements of neural activity.We believe the MPSs hold a promising translational potential for studying human pain etiology,screening new treatments,and validating novel therapeutics for human pain medicine.展开更多
Microphysiological systems(MPS)created with human-derived cells and biomaterial scaffolds offer a potential in vitro alternative to in vivo animal models.The adoption of three-dimensional MPS models has economic,ethic...Microphysiological systems(MPS)created with human-derived cells and biomaterial scaffolds offer a potential in vitro alternative to in vivo animal models.The adoption of three-dimensional MPS models has economic,ethical,regulatory,and scientific implications for the fields of regenerative medicine,metabolism/obesity,oncology,and pharmaceutical drug discovery.Key opinion leaders acknowledge that MPS tools are uniquely positioned to aid in the objective to reduce,refine,and eventually replace animal experimentation while improving the accuracy of the finding’s clinical translation.Adipose tissue has proven to be an accessible and available source of human-derived stromal vascular fraction(SVF)cells,a heterogeneous population available at point of care,and adipose-derived stromal/stem cells,a relatively homogeneous population requiring plastic adherence and culture expansion of the SVF cells.The adipose-derived stromal/stem cells or SVF cells,in combination with human tissue or synthetic biomaterial scaffolds,can be maintained for extended culture periods as three-dimensional MPS models under angiogenic,stromal,adipogenic,or osteogenic conditions.This review highlights recent literature relating to the versatile use of adipose-derived cells as fundamental components of three-dimensional MPS models for discovery research and development.In this context,it compares the merits and limitations of the adipose-derived stromal/stem cells relative to SVF cell models and considers the likely directions that this emerging field of scientific discovery will take in the near future.展开更多
The U.S.Food and Drug Administration(FDA)'s program documents regarding the animal-free approach for the efficacy,pharmacokinetics,and safety evaluation of new drug preclinical studies have been rolled out gradual...The U.S.Food and Drug Administration(FDA)'s program documents regarding the animal-free approach for the efficacy,pharmacokinetics,and safety evaluation of new drug preclinical studies have been rolled out gradually.This process has taken the FDA seven years.Starting from the reduction of funding for animal of data from organ-on-a-chip solely for pharmacodynamic studies[[1],[2],[3]],to the explicit proposal of the animal-free approach for pharmacodynamic studies in the FDA Modernization Act in Reference[4],and to the indication in 2025 that safety studies should also prioritize safety research data from in vitro microphysiological systems[5],this demonstrates the FDAs determination to gradually achieve the animal-free approach and also signals a profound paradigm shift in the field of drug research and development.This policy direction not only addresses the requirements of ethics and technological advancement but may also reshape the entire new drug development industrial chain.展开更多
New drug discovery is under growing pressure to satisfy the demand from a wide range of domains, especially from the pharmaceutical industry and healthcare services. Assessment of drug efficacy and safety prior to hum...New drug discovery is under growing pressure to satisfy the demand from a wide range of domains, especially from the pharmaceutical industry and healthcare services. Assessment of drug efficacy and safety prior to human clinical trials is a crucial part of drug development, which deserves greater emphasis to reduce the cost and time in drug discovery. Recent advances in microfabrication and tissue engineering have given rise to organ-on-a-chip, an in vitro model capable of recapitulating human organ functions in vivo and providing insight into disease pathophysiology, which offers a potential alternative to animal models for more efficient pre-clinical screening of drug candidates. In this review, we first give a snapshot of general considerations for organ-on-a-chip device design. Then, we comprehensively review the recent advances in organ-on-a-chip for drug screening. Finally, we summarize some key challenges of the progress in this field and discuss future prospects of organ-on-a-chip development. Overall,this review highlights the new avenue that organ-on-a-chip opens for drug development, therapeutic innovation, and precision medicine.展开更多
基金supported by Korea Technology and Information Promotion Agency(S3316767)National Research Foundation of Korea(2022R1A4A2000748 and 2022M3A9B6018217)+2 种基金Alchemist Project(KEIT 20018560,NTIS 1415184668)by of the Korea Evaluation Institute of Industrial TechnologyKorea Institute of Marine Science&Technology Promotion(KIMST,RS-2024-00402200)Hongik University Research Fund.
文摘The gut is a digestive organ that absorbs nutrients but also plays a vital role in immune response and defense against external compounds.The complex interaction between the gut microbiota and other organs including the immune system of the host has been known in various contexts,yielding the notion of‘axes’between the gut and other organs.While the presence of various gut-organ axes has been reported,the lack of adequate in vitro model systems for studying this interaction has restricted a deeper insight into these phenomena.Recently developed microphysiological systems(MPS),also known as organ-on-a-chip,allow researchers to study complex interactions between diverse organs,and here we provide a review of how recently developed gut-on-a-chip systems are used for building models of various diseases that were difficult to study.
基金The project was supported by the departmental start-up funds of Indiana University Bloomington,and in part by NSF grants(CCF-1909509,and CMMI-2025434)NIH awards(DP2AI160242,DA056242,and DA047858).
文摘pioids are commonly used for treating chronic pain.However,with continued use,they may induce tolerance and/or hyperalgesia,which limits therapeutic efficacy.The human mechanisms of opioid-induced tolerance and hyperalgesia are significantly understudied,in part,because current models cannot fully recapitulate human pathology.Here,we engineered novel human spinal microphysiological systems(MPSs)integrated with plug-and-play neural activity sensing for modeling human nociception and opioid-induced tolerance.Each spinal MPS consists of a flattened human spinal cord organoid derived from human stem cells and a 3D printed organoid holder device for plug-and-play neural activity measurement.We found that the flattened organoid design of MPSs not only reduces hypoxia and necrosis in the organoids,but also promotes their neuron maturation,neural activity,and functional development.We further demonstrated that prolonged opioid exposure resulted in neurochemical correlates of opioid tolerance and hyperalgesia,as measured by altered neural activity,and downregulation ofμ-opioid receptor expression of human spinal MPSs.The MPSs are scalable,cost-effective,easy-to-use,and compatible with commonly-used well-plates,thus allowing plug-and-play measurements of neural activity.We believe the MPSs hold a promising translational potential for studying human pain etiology,screening new treatments,and validating novel therapeutics for human pain medicine.
文摘Microphysiological systems(MPS)created with human-derived cells and biomaterial scaffolds offer a potential in vitro alternative to in vivo animal models.The adoption of three-dimensional MPS models has economic,ethical,regulatory,and scientific implications for the fields of regenerative medicine,metabolism/obesity,oncology,and pharmaceutical drug discovery.Key opinion leaders acknowledge that MPS tools are uniquely positioned to aid in the objective to reduce,refine,and eventually replace animal experimentation while improving the accuracy of the finding’s clinical translation.Adipose tissue has proven to be an accessible and available source of human-derived stromal vascular fraction(SVF)cells,a heterogeneous population available at point of care,and adipose-derived stromal/stem cells,a relatively homogeneous population requiring plastic adherence and culture expansion of the SVF cells.The adipose-derived stromal/stem cells or SVF cells,in combination with human tissue or synthetic biomaterial scaffolds,can be maintained for extended culture periods as three-dimensional MPS models under angiogenic,stromal,adipogenic,or osteogenic conditions.This review highlights recent literature relating to the versatile use of adipose-derived cells as fundamental components of three-dimensional MPS models for discovery research and development.In this context,it compares the merits and limitations of the adipose-derived stromal/stem cells relative to SVF cell models and considers the likely directions that this emerging field of scientific discovery will take in the near future.
文摘The U.S.Food and Drug Administration(FDA)'s program documents regarding the animal-free approach for the efficacy,pharmacokinetics,and safety evaluation of new drug preclinical studies have been rolled out gradually.This process has taken the FDA seven years.Starting from the reduction of funding for animal of data from organ-on-a-chip solely for pharmacodynamic studies[[1],[2],[3]],to the explicit proposal of the animal-free approach for pharmacodynamic studies in the FDA Modernization Act in Reference[4],and to the indication in 2025 that safety studies should also prioritize safety research data from in vitro microphysiological systems[5],this demonstrates the FDAs determination to gradually achieve the animal-free approach and also signals a profound paradigm shift in the field of drug research and development.This policy direction not only addresses the requirements of ethics and technological advancement but may also reshape the entire new drug development industrial chain.
基金financial support from the National Key R&D Program of China (2019YFA0709200)the National Natural Science Foundation of China (21874066, and 61804076)+3 种基金the Key Research and Development Program of Jiangsu Province (BE2021373, China)the Natural Science Foundation of Jiangsu Province (BK20180700, and BK20200336, China)the Fundamental Research Funds for Central Universities (China)the Program for Innovative Talents and Entrepreneur in Jiangsu (China)。
文摘New drug discovery is under growing pressure to satisfy the demand from a wide range of domains, especially from the pharmaceutical industry and healthcare services. Assessment of drug efficacy and safety prior to human clinical trials is a crucial part of drug development, which deserves greater emphasis to reduce the cost and time in drug discovery. Recent advances in microfabrication and tissue engineering have given rise to organ-on-a-chip, an in vitro model capable of recapitulating human organ functions in vivo and providing insight into disease pathophysiology, which offers a potential alternative to animal models for more efficient pre-clinical screening of drug candidates. In this review, we first give a snapshot of general considerations for organ-on-a-chip device design. Then, we comprehensively review the recent advances in organ-on-a-chip for drug screening. Finally, we summarize some key challenges of the progress in this field and discuss future prospects of organ-on-a-chip development. Overall,this review highlights the new avenue that organ-on-a-chip opens for drug development, therapeutic innovation, and precision medicine.
